Renee Wu

  • Indianapolis, IN

  • Yale U. (2014)

  • Immunology

  • Not Available

  • Functions of cDC1 for anti-tumor CD4 and CD8 T cell responses

Research

Cancer immunotherapies have revolutionized the treatment of malignancies, but these therapeutics still face enormous challenges and limited efficacy in many patients. To overcome these limitations, improved strategies for CD8 T cell-targeted therapies require an increased understanding of how other immune players, particularly CD4 helper T cells, can promote cytotoxic CD8 T cell responses against cancer neoantigens. Conventional type 1 dendritic cells (cDC1) are thought to perform antigen cross-presentation, which is required to prime CD8 T cells. We have recently shown that cDC1 also prime CD4 T cells in the context of tumor antigens. CD4 T cells are also considered to help CD8 T cell responses through a variety of mechanisms, including a process whereby CD4 T cells ‘license’ cDC1 in a CD40-dependent pathway. My research seeks to determine the functions of cDC1 in initiating CD4 and CD8 T cell anti-tumor responses and the downstream mechanisms of CD40 signaling in the cDC1.

Graduate Publications:

Bagadia P, O'Connor KW, Wu R, Ferris ST, Ward JP, Schreiber RD, Murphy TL, Murphy KM. 2021 Bcl6-Independent In Vivo Development of Functional Type 1 Classical Dendritic Cells Supporting Tumor Rejection. J Immunol, ():ji1901010.

Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT 4th, Bagadia P, Liu T, Briseño CG, Li L, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM. 2020 cDC1 prime and are licensed by CD4 + T cells to induce anti-tumour immunity. Nature, ():Online ahead of print.

Durai V, Bagadia P, Granja JM, Satpathy AT, Kulkarni DH, Davidson JT 4th, Wu R, Patel SJ, Iwata A, Liu TT, Huang X, Briseño CG, Grajales-Reyes GE, Wöhner M, Tagoh H, Kee BL, Newberry RD, Busslinger M, Chang HY, Murphy TL, Murphy KM. 2019 Cryptic activation of an Irf8 enhancer governs cDC1 fate specification. Nat Immunol, 20(9):1161-73.

Last Updated: 9/29/2021 2:50:31 PM

Back to top